Related Experiment Video

Updated: Jun 7, 2025

A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer
07:35

A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer

Published on: December 26, 2016

40.9K

Mechanisms of endocrine resistance in hormone receptor-positive breast cancer

Yuan Gao1, Yang Yu1, Mingqing Zhang1

  • 1Cancer Center, The First Hospital of Jilin University, Changchun, Jilin, China.

Frontiers in Oncology
|November 15, 2024
PubMed

Insights

Hormone receptor-positive breast cancer can resist endocrine therapy through various mechanisms. Understanding these pathways is key to overcoming treatment resistance in advanced breast cancer.

Area of Science:

  • Oncology
  • Endocrinology
  • Molecular Biology

Background:

  • Hormone receptor-positive breast cancer can recur or metastasize long after initial diagnosis.
  • Hormone receptor expression often persists in recurrent or metastatic cancer cells.
  • Endocrine therapy is a primary treatment for hormone receptor-positive breast cancer, but resistance is common.

Purpose of the Study:

  • To review the mechanisms of endocrine resistance in hormone receptor-positive advanced breast cancer.
  • To discuss recent research advancements and future prospects in overcoming endocrine resistance.

Main Methods:

  • Review of previous studies on endocrine resistance mechanisms.
  • Analysis of identified molecular pathways involved in resistance.

Main Results:

  • Mechanisms include epigenetic abnormalities in the estrogen receptor (ER) genome.
  • Activation of ER-independent ligands contributes to resistance.
  • Alterations in signaling pathways (PI3K/AKT/mTOR, Notch, NF-κB, FGFR, IRE1-XBP1) are implicated.

Conclusions:

  • Endocrine resistance in hormone receptor-positive advanced breast cancer is multifactorial.
  • Continued research into these mechanisms is crucial for developing effective therapeutic strategies.
  • Understanding resistance pathways offers hope for improved patient outcomes.
Keywords:
breast cancerendocrine treatmenthormone receptor-positivemechanismsresistance

More Related Videos

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

8.2K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.8K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Target Cell Response to Hormones01:22

Target Cell Response to Hormones

Hormones intricately bind to receptors on the surface or within target cells, initiating a cascade of cellular responses.
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
2.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Endocrine Signaling01:45

Endocrine Signaling

Endocrine cells produce hormones to communicate with remote target cells found in other organs. The hormone reaches these distant areas using the circulatory system. This exposes the whole organism to the hormone but only those cells expressing hormone receptors or target cells are affected. Thus, endocrine signaling induces slow responses from its target cells but these effects also last longer.
64.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.0K